Skip to main content

Table 1 Summary of patient demographics and treatment data

From: Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study

SMA type

SMN2 copy number

Nusinersen treatment initiation

Onasemnogene Abeparvovec treatment

last follow-up

age [d]

age [d]

body weight [kg]

nutritional and/or ventilatory support; scoliosis

age [d]

nutritional an/or ventilatory support; scoliosis

1b

2

39

102

6,4

–

606

S

1a

2

80

312

7,6

N (gs)

933

N (gs), S

1b

2

–

75

5,3

–

502

S

1b

2

–

97

6,0

–

518

N (gs), S

1b

2

–

79

4,8

–

494

N (ng), V

1b

2

–

192

5,8

–

374

–

2

3 SMN hybrid gene copies

–

527

8,7

–

830

–

ps

3

–

19

4,5

–

286

–

ps

3 SMN hybrid gene copies

–

37

4,0

–

340

–

  1. ps pre-symptomatic, N nutritional support (gs gastrostomy, ng nasogastric tube), V ventilatory support, S scoliosis